IL17A and neoplasm: In these cases, after the diagnosis of the tumor, 30 patients (61%) received an anti-IL17 drug: 20 patients (41%) received secukinumab, 7 patients (14%) received brodalumab, and 3 patients (6%) received ixekizumab.